Article
Cell cycle phenotype-based optimization of G2-abrogating peptides yields CBP501 with a unique mechanism of action at the G2 checkpoint.
Molecular cancer therapeutics - 1 Jan 2007
Sha Shi-Ken, Sato Takuji, Kobayashi Hidetaka, Ishigaki Machiyo, Yamamoto Sayaka, Sato Hitoshi, Takada Asako, Nakajyo Sigetosi, Mochizuki Yasuo, Friedman Jonathan M, Cheng Fong-Chi, Okura Takashi, Kimura Ryohei, Kufe Donald W, Vonhoff Daniel D, Kawabe Takumi
Abstract excerpt
Cell cycle G(2) checkpoint abrogation is an attractive strategy for sensitizing cancer cells to DNA-damaging anticancer agent without increasing adverse effects on normal cells. However, there is no single proven molecular target for this therapeutic approach. High-throughput screening for molecules inhibiting CHK1, a kinase that is essential for the G(2) checkpoint, has not yet yielded therapeutic G(2)...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.